The core challenge that PRADA addresses is a long-standing bottleneck in proximity labeling. The most widely used tools, such as APEX2 and TurboID, genetically fuse an engineered enzyme to a protein of interest. The enzyme then converts a supplied small molecule into a reactive species that tags nearby biomolecules, which can later be fished out and identified by mass spectrometry or sequencing. The catch is the trigger. APEX2 requires a bolus of exogenous hydrogen peroxide, a reactive oxidant that damages cells and diffuses poorly through intact tissues. TurboID requires biotin, which works in vivo but generates its own background labeling. Neither approach has proven ideal for the delicate, three-dimensional environment of a living organism.

The Shanghai- and Singapore-based team, led by Shuo Han of the Chinese Academy of Sciences together with Yue Wan of the Genome Institute of Singapore, took a different route: instead of supplying hydrogen peroxide directly, they engineered the system to make it on the spot. PRADA pairs a genetically fused peroxidase with an engineered D-amino acid oxidase, or DAAO, derived from the yeast Rhodotorula gracilis. When researchers deliver a nonproteinogenic D-amino acid such as D-phenylalanine or D-alanine — molecules that animal cells largely ignore — the oxidase converts them into hydrogen peroxide right next to the peroxidase. That locally generated oxidant then activates the peroxidase, which converts phenol probes such as biotin-phenol into short-lived radicals that covalently tag whatever proteins or nucleic acids sit within roughly a few tens of nanometers.

The engineering itself was nontrivial. The team used structural modeling and rational mutagenesis to delete a flexible C-terminal loop of the R. gracilis oxidase, producing a monomeric variant that fuses cleanly with APEX2 without disrupting either enzyme’s activity. Extended data show the researchers systematically tested fusion orientations, split-enzyme designs and D-amino acid concentrations, using fluorescence assays to confirm that the cascade produces hydrogen peroxide efficiently and that the labeling signal colocalizes precisely with the tagged protein’s known subcellular address. When the two enzymes were expressed separately rather than fused, labeling dropped sharply, confirming that the reaction is genuinely confined to the immediate vicinity of the fusion protein.

That spatial confinement is what makes the method safe enough for living animals. Because the hydrogen peroxide is generated in situ at nanometer scales and consumed almost immediately by the peroxidase, it never accumulates to toxic levels. The researchers measured malondialdehyde levels, a marker of lipid peroxidation, and protein carbonylation after PRADA labeling and found both below detection limits or unchanged compared with controls. Mitochondrial superoxide, a sensitive indicator of oxidative stress, was actually lower in PRADA-labeled cells than in cells labeled conventionally with APEX2 and exogenous peroxide. Cell viability assays showed no measurable harm from the D-amino acid treatment itself. In effect, PRADA converts the most dangerous step of proximity labeling into a self-limiting, locally contained reaction.

The versatility of the platform is striking. In cultured cells, the team targeted PRADA to the nucleus, nucleolus, endoplasmic reticulum, plasma membrane and mitochondria, and in each case recovered proteomic profiles consistent with the known composition of those compartments. They also showed that PRADA can drive functional polymer assembly — the genetically targeted chemical assembly of conducting or insulating materials inside living cells — extending the technique beyond mapping into materials synthesis. And, crucially, they demonstrated that the peroxidase step can label RNA as well as protein, opening a door that most proximity-labeling systems leave closed.

That RNA reactivity became the foundation of the study’s most inventive application. When peroxidase radicals oxidize RNA, they leave behind chemical lesions that cause reverse transcriptase to misread bases during cDNA synthesis. The team realized these misincorporations could be read as a molecular fingerprint of RNA structure: nucleotides that are chemically accessible — that is, single-stranded and exposed — accumulate more mutations than nucleotides buried inside base-paired helices. Building on the logic of mutational profiling sequencing, they developed PRADA-MaPseq, a strategy that converts peroxidase labeling directly into a spatiotemporally resolved map of RNA secondary structure inside living cells.

They benchmarked PRADA-MaPseq against the well-established mitochondrial DMS-MaPseq datasets, showing that uracil and guanine reactivity scores accurately reproduce known structures of mitochondrial messenger RNAs, with area-under-the-curve values reaching 0.60 to 0.82 across transcripts and inter-experimental correlation coefficients as high as 0.96 for individual transcripts. The approach worked with both 4-thiouridine and 6-selenoguanosine metabolic labeling, and the team optimized reverse transcriptase choice to maximize mutational signal. In short, they turned a proximity-labeling enzyme into a structure-probing reagent that reports on RNA folding in a defined cellular compartment at a defined moment in time.

The payoff came in a mouse xenograft model. The researchers implanted HEK293T cells expressing mitochondria-targeted PRADA into immunodeficient mice, then administered D-amino acids and phenol probes systemically. Labeling proceeded efficiently inside the tumors in living animals. Proteomic analysis recovered the expected mitochondrial proteome, transcriptomic enrichment captured mitochondrial RNAs with high specificity, and PRADA-MaPseq yielded the first in vivo structurome of mitochondrial RNA within a living mammalian tumor. Comparing these in vivo structure maps with in vitro measurements of the same transcripts revealed systematic differences — evidence that RNA folding inside a living organism is actively shaped by its environment rather than being a fixed property of the sequence.

Those differences carried biological meaning. The team focused on LRPPRC, a mitochondrial RNA-binding protein known to organize the folding of the mitochondrial transcriptome. When they knocked down LRPPRC in the xenografts, changes in RNA structure propagated to changes in mitochondrial gene expression, demonstrating that RNA architecture functions as a regulatory layer controlling how mitochondrial genes are read. This finding elevates the structurome from a descriptive atlas to a mechanistic insight: the three-dimensional shapes of RNAs inside mitochondria help determine how much protein the organelle makes, and those shapes are tunable in vivo.

Beyond mitochondria, the breadth of validated applications suggests PRADA could become a workhorse across biology. The team demonstrated labeling in the cytoplasm and nuclei of body wall muscle cells in Caenorhabditis elegans, recovering nuclear-enriched transcripts and detecting retained introns as expected; in rat neurons and Drosophila; and in zebrafish. Because the trigger molecule — a simple D-amino acid — is cell-permeable, inexpensive and largely inert, the method should scale to tissues and organisms where peroxide bolus delivery is impractical, such as dense neural tissue, developing embryos or intact tumors. The authors have filed patent applications, and the analysis code for RNA structuromics is freely available on GitHub under an MIT license, with sequencing and proteomic data deposited in public repositories.

Limitations remain, as with any new technology. The labeling window is measured in tens of minutes rather than seconds, so fast molecular events may still escape capture. The peroxidase chemistry, while gentler than exogenous peroxide, still relies on radical intermediates whose diffusion radius sets the spatial resolution. And the D-amino acid oxidase must be carefully engineered for each fusion context to avoid perturbing the protein under study. Nevertheless, PRADA represents a genuine conceptual advance: it decouples proximity labeling from externally supplied oxidants, unifies protein, RNA and polymer chemistries under one enzymatic umbrella, and — for the first time — brings RNA structure mapping into living animals. If the platform generalizes as its developers hope, the spatial organization of biomolecules in health and disease may soon be readable not just in culture dishes, but in the bodies of living organisms, one D-amino acid at a time.

Subject of Research: An engineered D-amino-acid-activated peroxidase cascade for in vivo multiomic proximity labeling of proteins and RNA structures

Article Title: Multiomic proximity labeling in vivo by D-amino-acid-activated peroxidase reaction

Article References: Liu, J., Han, J., Wang, Y., Song, M., Zhu, J., Liang, Y., Chen, F., Liu, Z., Yan, X., Wang, Z., Peng, W., Tu, R., Zhang, Z., Zhong, B., Sun, H., Yin, J., Chang, J., Long, Y., Men, Y., … Han, S. (2026). Multiomic proximity labeling in vivo by D-amino-acid-activated peroxidase reaction. Nature Chemical Biology. https://doi.org/10.1038/s41589-026-02336-5

Image Credits: AI Generated

DOI: 10.1038/s41589-026-02336-5

Keywords: proximity labeling, PRADA, D-amino acid oxidase, APEX2, RNA structure, structurome, mitochondria, spatial proteomics, chemical biology, in vivo imaging, xenograft, LRPPRC

The technique, developed by Iwona Nowak, Ahsan H. Polash, Hang T. Huynh, Mahekdeep Kaur and colleagues in the laboratories of Aishe A. Sarshad, Markus Hafner, and Daniel Benhalevy, fuses two powerful approaches that had never been married at this scale. The first is APEX2-based proximity labeling, an enzymatic tagging system that marks proteins and nucleic acids within a narrow radius of a genetically targeted protein. The second is 4-thiouridine-enhanced ultraviolet crosslinking, which covalently locks RNA-binding proteins onto their RNA targets and allows precise identification of crosslinked nucleotides. By combining these with sequential affinity purifications, first for the RNA-binding protein of interest and then for the biotin tag, the researchers built a pipeline that isolates only those protein-RNA contacts that occurred in the marked compartment.

The logic of the method is elegant in its layering. A protein of interest, such as the RNA-binding factor being studied, is expressed as a fusion with APEX2, a peroxidase that in the presence of biotin-phenol and hydrogen peroxide converts nearby molecules into biotin-tagged derivatives. Cells are first treated with 4-thiouridine, which is incorporated into newly synthesized RNA and dramatically strengthens ultraviolet-induced crosslinking between RNA and any protein touching it, a strategy borrowed from fPAR-CLIP protocols. When ultraviolet light fires, RNA-binding proteins are frozen onto their targets with nucleotide precision. APEX2 then labels everything in its immediate vicinity with biotin, creating a spatial signature.

What follows is a double selection. The researchers purify the RNA-binding protein and its crosslinked RNA fragments through an initial affinity step, recovering crosslinked RNA with mutations that reveal the exact binding sites, the hallmark of enhanced crosslinking-and-immunoprecipitation approaches. They then recover only those complexes that also carry the APEX2-deposited biotin tag in a second purification. A transcript must pass both filters to be counted: it must have been physically touched by the protein and must have been within the proximity-labeling radius, effectively bracketing the interaction in space and time. The result is a map of protein-RNA contacts that is simultaneously compartment-specific and nucleotide-resolved.

Control experiments were central to validating the approach. The team confirmed that APEX2 fusion proteins localized correctly to their intended compartments and that proximity-dependent biotinylation was restricted to the expected neighborhoods, presenting this evidence across multiple supplementary figures alongside imaging and immunoblot analyses. Without accurate spatial confinement, any apparent compartment specificity could simply reflect leakage or overexpression artifacts, so establishing the fidelity of the labeling step was essential before biological conclusions could be drawn.

With the method proven, the researchers turned it loose on three of the most intensively studied RNA-binding proteins: AGO2, the central effector of the microRNA silencing machinery; YBX1, a multifunctional nucleic acid-binding protein involved in mRNA stability and translation; and ELAVL1, better known in some circles as HuR, a regulator of mRNA stability and stress responses. All three proteins are known to operate in multiple cellular compartments, making them ideal test cases for a technology designed to disentangle location-dependent behavior.

The findings were striking. Each of the three proteins displayed distinct, compartment-specific RNA-binding patterns, targeting different sets of transcripts and even different sequence contexts depending on where in the cell it was acting. Importantly, the researchers found that these spatial differences arose through canonical motif recognition: the same proteins continued to recognize their characteristic sequence motifs in each compartment, but the repertoire of available targets, and thus the functional consequences of binding, shifted dramatically with location. In other words, the proteins did not change their binding preferences so much as their access to substrates changed, partitioning the accessible RNA targets and reshaping each protein’s regulome across the cell.

This partitioning concept has broad implications. For AGO2, compartment-specific mapping opens a window onto how microRNA targeting might differ between the cytoplasm, where canonical silencing occurs, and other locales where AGO2 has been implicated in less conventional roles. For YBX1 and ELAVL1, both implicated in cancer biology and stress physiology, knowing which transcripts are bound in which compartments could clarify how these proteins execute distinct functions from seemingly identical biochemical activities. The method essentially converts a single flat binding profile into a set of spatially annotated maps, revealing that what looked like one interactome is actually several overlapping ones.

Technically, RBProximity-CLIP also demonstrates the value of the 4-thiouridine enhancement inherited from fPAR-CLIP. Enhanced crosslinking increases crosslinking efficiency and yields the characteristic signature of crosslink-induced mutations, allowing binding sites to be pinpointed to individual nucleotides. Combined with proximity tagging, this delivers a rare combination of spatial and sequence resolution in a single experiment, something neither classical CLIP nor proximity labeling alone can provide. The authors provide detailed reagent lists, including antibodies, detection reagents for imaging and immunoblotting, and oligonucleotide sequences for library preparation, alongside full-length uncropped gel and blot images, underscoring the reproducibility infrastructure that accompanies methodological advances of this kind.

The work was a genuinely international effort, jointly led from the University of Gothenburg’s Wallenberg Centre for Molecular and Translational Medicine, the RNA Molecular Biology Laboratory at the National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, and Tel Aviv University, with support from the Swedish Research Council, the Knut and Alice Wallenberg Foundation, the Swedish Society for Medical Research, the National Institutes of Health Intramural Research Program, the Israel Science Foundation, and the Hellenic Foundation for Research and Innovation. Published as an open-access article in Genome Biology, the study arrives at a moment when the field is increasingly aware that spatial context is not a luxury but a fundamental dimension of gene regulation. As RBProximity-CLIP is adopted and extended, it promises to turn the cell from a featureless bag of molecules into a mapped territory, where every protein-RNA encounter has an address, and where the grammar of gene expression can finally be read with both sequence and location in view.

Subject of Research: A subcellular-resolution RNA-binding protein mapping method combining proximity labeling and enhanced crosslinking

Article Title: RBProximity-CLIP enables subcellular mapping of RNA-binding protein interactions at nucleotide resolution

Article References: Nowak, I., Polash, A. H., Huynh, H. T., Kaur, M., Lobo, V., Scutenaire, J., Fong, M., Alluhaibi, G., Anastasakis, D. G., Hafner, M., Benhalevy, D., & Sarshad, A. A. (2026). RBProximity-CLIP enables subcellular mapping of RNA-binding protein interactions at nucleotide resolution. Genome Biology. https://doi.org/10.1186/s13059-026-04278-6

Image Credits: AI Generated

DOI: 10.1186/s13059-026-04278-6

Keywords: RNA-binding proteins, RBProximity-CLIP, proximity labeling, APEX2, CLIP-seq, AGO2, YBX1, ELAVL1, 4-thiouridine, subcellular resolution, protein-RNA interactions, Genome Biology